Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
3.64 ^USD	-1.89%		-2.41%	-36.47%

05-09	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	MT
05-07	Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 11, 2024 at 04:26 pm

Caribou Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 102.07 million compared to USD 99.42 million a year ago. Basic loss per share from continuing operations was USD 1.38 compared to USD 1.64 a year ago.

Latest news about Caribou Biosciences, Inc.

Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	05-09	MT
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	04-05	MT
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	04-04	MT
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04-04	CI
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	03-25	MT
HC Wainwright Adjusts Caribou Biosciences Price Target to $24 From $23, Maintains Buy Rating	03-19	MT
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer	01-07	CI
North American Morning Briefing : Traders Await FOMC, Powell	12-13	DJ
Caribou Biosciences Says it Reached Alignment With FDA on Phase 3 Trial Plan for Lymphoma Treatment	12-13	MT
Caribou Biosciences Shares Rise 4.1% as FDA Approves Lymphoma Trial	12-12	DJ
Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023	12-12	CI
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024	12-12	CI
Cantor Fitzgerald Initiates Caribou Biosciences at Neutral Rating	11-08	MT
Caribou Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board	11-06	CI
US FDA Clears Caribou Biosciences' CB-012 Cancer Drug Candidate for Human Study	23-10-18	MT
Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	23-10-18	CI
Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer	23-09-27	CI
AbbVie Elects to Terminate the Collaboration and License Agreement with Caribou Biosciences, Inc	23-09-26	CI
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to S&P Biotechnology Select Industry Index	23-09-18	CI
Certain Restricted Stock Units of Caribou Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2023.	23-09-11	CI
Certain Stock Options of Caribou Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2023.	23-09-11	CI

Chart Caribou Biosciences, Inc.

Duration

Period

More charts

Company Profile

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Caribou Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.64 USD

Average target price

19.75 USD

Spread / Average Target

+442.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARIBOU BIOSCIENCES, INC.	-36.47%	329M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+47.41%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research